



**CAPE TOWN INTERNATIONAL CONVENTION CENTRE, SOUTH AFRICA
3 – 8 DECEMBER 2016**

Seminar is open – please pre-register online to secure a seat

Sunday, 4 December 2016

**Quality needs for Molecular TB/HIV and HPV diagnostic assays applied in clinical laboratories:
An ACTG sponsored workshop
08h00-12h00 Room 2.61-2.63**

The **AIDS Clinical Trials Group** (ACTG), established in 1987, is one of the largest global HIV clinical trials organizations playing a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV and AIDS. ACTG supports the largest network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities. This workshop therefore focuses on quality needs for clinical laboratories performing molecular and morphological diagnostics for TB, HIV and HPV, and shares experiences of successful introduction of clinical trial related EQA into pathology laboratories in resource limited settings.

Target Audience

Anatomical and clinical pathologists, molecular scientists and technologists requiring updated information on clinically relevant diagnostics, with a special focus on **quality requirements** which now also need to extend to point of care and field based testing.

Presentations

Focus on Tuberculosis

Brief overview of molecular TB diagnostics routinely applied in clinical laboratories	Dr Andrew Whitelaw
Experience from quality monitoring options for molecular TB diagnostics (verification and EQA)	Ms Anura David
Molecular TB diagnostic's clinical interpretation and lessons learned from the field.	Dr Pedro Da Silva

Focus on HIV and HPV

Quality needs for HIV VL and EID in an era of POC testing	Prof Lelsey Scott
Experience from VQA, SAVQA and the role of DBS on HIV VL testing	Dr Robert Coombs & Prof Lesley Scott
The effect of pre-exposure antiretroviral prophylaxis (PrEP) on the laboratory staging of acute/early HIV-1 infection	Dr Robert Coombs
Quality needs for molecular HPV testing and introducing new testing platforms for HPV	Dr Carole Wallis
Experience from quality implementation in two trials: A5282 PERC and A5263/64 KS PERC	Dr Pamela Michelow & Dr Neal Wetherall

**SEMINARS ARE DESIGNED FOR A RANGE OF AUDIENCES.
PLEASE JOIN US TO SHARE BEST PRACTICES, ACQUIRE KNOWLEDGE,
AND DEBATE INNOVATIVE APPROACHES FOR MEETING
GLOBAL HEALTH PRIORITIES.**

